Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalantercept in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT01720173Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Nov 2012
- Primary completion
- Oct 2015
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of dalantercept in ovarian epithelial cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by GOG Foundation. Started Nov 2012; status: completed.
02
Drugs
dalantercept
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT01720173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01720173.